Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of AGIOS PHARMACEUTICALS, INC. from 31 Dec 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
AGIOS PHARMACEUTICALS, INC. annual and quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Dec 2011 to 31 Dec 2025.
  • AGIOS PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 30 Sep 2025 was $103,433,000, a 110% decline year-over-year.
  • AGIOS PHARMACEUTICALS, INC. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2025 was $413,797,000, a 158% decline from 2024.
  • AGIOS PHARMACEUTICALS, INC. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $717,969,000.
  • AGIOS PHARMACEUTICALS, INC. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $352,088,000, a 52% decline from 2022.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)

AGIOS PHARMACEUTICALS, INC. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $413,797,000 -$1,131,766,000 -158% 01 Jan 2025 31 Dec 2025 10-K 12 Feb 2026 2025 FY
2024 $717,969,000 +$1,070,057,000 01 Jan 2024 31 Dec 2024 10-K 12 Feb 2026 2025 FY
2023 $352,088,000 -$120,287,000 -52% 01 Jan 2023 31 Dec 2023 10-K 12 Feb 2026 2025 FY
2022 $231,801,000 +$124,709,000 +35% 01 Jan 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
2021 $356,510,000 -$27,205,000 -8.3% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $329,305,000 -$27,897,000 -9.3% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
2019 $301,408,000 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
2016 $198,471,000 -$80,739,000 -69% 01 Jan 2016 31 Dec 2016 10-K 16 Feb 2017 2016 FY
2015 $117,732,000 -$63,802,000 -118% 01 Jan 2015 31 Dec 2015 10-K 16 Feb 2017 2016 FY
2014 $53,930,000 -$15,102,000 -39% 01 Jan 2014 31 Dec 2014 10-K 16 Feb 2017 2016 FY
2013 $38,828,000 -$15,902,000 -69% 01 Jan 2013 31 Dec 2013 10-K 26 Feb 2016 2015 FY
2012 $22,926,000 -$6,427,000 -39% 01 Jan 2012 31 Dec 2012 10-K 24 Feb 2015 2014 FY
2011 $16,499,000 01 Jan 2011 31 Dec 2011 10-K 18 Mar 2014 2013 FY

AGIOS PHARMACEUTICALS, INC. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $103,433,000 -$1,104,468,000 -110% 01 Jul 2025 30 Sep 2025 10-Q 30 Oct 2025 2025 Q3
Q3 2024 $1,001,035,000 +$1,092,359,000 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2025 2025 Q3
Q3 2023 $91,324,000 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024 2024 Q3
Q4 2021 $356,510,000 $98,584,000 -$14,043,000 -17% 01 Oct 2021 31 Dec 2021 10-K 24 Feb 2022 2021 FY
Q3 2021 $342,467,000 $84,259,000 -$5,084,000 -6.4% 01 Jul 2021 30 Sep 2021 10-K 24 Feb 2022 2021 FY
Q2 2021 $337,383,000 $82,790,000 -$1,295,000 -1.6% 01 Apr 2021 30 Jun 2021 10-K 24 Feb 2022 2021 FY
Q1 2021 $336,088,000 $90,877,000 -$6,783,000 -8.1% 01 Jan 2021 31 Mar 2021 10-K 24 Feb 2022 2021 FY
Q4 2020 $329,305,000 $84,541,000 01 Oct 2020 31 Dec 2020 10-K 24 Feb 2022 2021 FY
Q3 2020 $79,175,000 01 Jul 2020 30 Sep 2020 10-K 24 Feb 2022 2021 FY
Q2 2020 $81,495,000 01 Apr 2020 30 Jun 2020 10-K 24 Feb 2022 2021 FY
Q1 2020 $84,094,000 01 Jan 2020 31 Mar 2020 10-K 24 Feb 2022 2021 FY
Q3 2015 $40,257,000 -$43,513,000 -1336% 01 Jul 2015 30 Sep 2015 10-Q 06 Nov 2015 2015 Q3
Q4 2014 $53,930,000 $26,642,000 -$14,429,000 -118% 01 Oct 2014 31 Dec 2014 10-K 16 Feb 2017 2016 FY
Q3 2014 $39,501,000 $3,256,000 +$14,312,000 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015 2015 Q3
Q2 2014 $53,813,000 $18,296,000 -$9,775,000 -115% 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2014 2014 Q2
Q1 2014 $44,038,000 $12,248,000 -$5,210,000 -74% 01 Jan 2014 31 Mar 2014 10-Q 09 May 2014 2014 Q1
Q4 2013 $38,828,000 $12,213,000 01 Oct 2013 31 Dec 2013 10-K 26 Feb 2016 2015 FY
Q3 2013 $11,056,000 -$5,959,000 -117% 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014 2014 Q3
Q2 2013 $8,521,000 -$2,420,000 -40% 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014 2014 Q2
Q1 2013 $7,038,000 01 Jan 2013 31 Mar 2013 10-Q 09 May 2014 2014 Q1
Q3 2012 $5,097,000 01 Jul 2012 30 Sep 2012 10-Q 07 Nov 2013 2013 Q3
Q2 2012 $6,101,000 01 Apr 2012 30 Jun 2012 10-Q 05 Sep 2013 2013 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.